• Lanabecestat (AZD3293): Mapping the BACE1 Window

  2026-09-24

  Lanabecestat offers translational researchers a potent tool for studying BACE1 and amyloid-beta production. Evidence from neuronal cultures suggests that the biological consequences of inhibition depend on the degree of amyloid-beta reduction, making exposure-response design and paired synaptic measurements central to rigorous Alzheimer’s disease research.

• Regorafenib Workflows for Melanoma Research

  2026-09-23

  Use Regorafenib (BAY 73-4506) to connect multikinase inhibition with practical assays of melanoma growth, motility, apoptosis, and RRM2-associated signaling. This workflow pairs dose-response controls with migration and mechanistic readouts to help distinguish reduced aggressiveness from general cytotoxicity.

• PD0325901: From MEK Signaling to TERT

  2026-09-23

  PD0325901 is a selective MEK inhibitor for dissecting RAS/RAF/MEK/ERK signaling, cancer phenotypes, and transcriptional regulation. This article develops an assay-centered framework linking pathway inhibition to TERT chromatin control in human pluripotent stem cells.

• APEX2 Enables TERT Expression in Human Stem Cells

  2026-09-22

  This preprint identifies APEX2 as a selective DNA repair factor required for efficient TERT expression and telomerase activity in human embryonic stem cells. RNA-seq and chromatin immunoprecipitation connect APEX2 activity with repetitive DNA elements, particularly MIR sequences within the TERT locus, suggesting that repair of damage-prone repeats may influence transcription.

• Single-Fibre Mapping of Nucleosome Distortion

  2026-09-22

  The reference study introduces IDLI, a computational framework that uses long-read single-molecule footprinting to map structurally distinct nucleosomes and protein–DNA interactions on individual chromatin fibres. Its results indicate that nucleosome distortion is widespread, developmentally regulated, and associated with transcription-factor occupancy, providing a new way to study chromatin accessibility beyond average population-level measurements.

• CUDC-907 Dual PI3K and HDAC Inhibitor Guide

  2026-09-21

  CUDC-907 is a dual PI3K and HDAC inhibitor for controlled in vitro studies of PI3K/AKT signaling, HDAC activity, cell-cycle progression, and apoptosis. This dossier-based guidance covers formulation, starting conditions, readout selection, and QC; the compound is for scientific research only and not for diagnostic or medical use.

• AICAR phosphate (Acadesine): Assay Guide

  2026-09-21

  A scenario-based guide to using AICAR phosphate (Acadesine), SKU B1211, in viability, proliferation, and apoptosis workflows. It covers dose selection, solution handling, orthogonal readouts, cross-domain interpretation, and practical criteria for evaluating product reliability.

• PLAC1 Targeting in Clear Cell Renal Cell Carcinoma

  2026-09-20

  A 2025 Cellular Signalling study identifies PLAC1 as a prognostic biomarker and candidate molecular target in clear cell renal cell carcinoma (ccRCC). By combining TCGA analysis, protein-level validation, PLAC1 knockdown, and high-throughput virtual screening, the researchers nominate Amaronol B and Canagliflozin as compounds that reduce PLAC1-associated ccRCC progression in vitro.

• Trametinib (GSK1120212): Assay Reliability

  2026-09-19

  This scenario-driven guide shows how Trametinib (GSK1120212), SKU A3018, can help researchers interpret variable viability, proliferation, and cytotoxicity results through mechanism-aware experimental design. It covers model selection, DMSO stock preparation, pathway-confirming readouts, heterogeneity, and practical vendor evaluation.

• BI-1347: CDK8 Signaling Workflow Guide

  2026-09-18

  BI-1347 is a potent, selective small-molecule probe for testing target-dependent signaling and antitumor biology. This workflow translates CDK8/19-focused findings from osteoarthritis research into practical cell-based, inflammatory, transcriptomic, and translational assay designs.

• Nilotinib (AMN-107) Assay Workflows

  2026-09-18

  Build more informative kinase-response experiments with Nilotinib (AMN-107), from BCR-ABL target engagement to separate measurements of growth arrest and cell death. This workflow combines practical dosing guidance, mutation-aware comparisons, and troubleshooting for chronic myeloid leukemia research and KIT-driven models.

• CUDC-907: Practical Dual PI3K/HDAC Workflow

  2026-09-17

  CUDC-907 provides a research tool for examining concurrent PI3K/AKT signaling pathway inhibition and histone deacetylase inhibition in controlled cancer cell assays. This guide covers preparation, exposure, controls, and endpoint QC; the compound is for research use only and should not be used for diagnostic, therapeutic, or clinical applications.

• RSL3: A Context-Aware GPX4 Assay Strategy

  2026-09-17

  RSL3 is a glutathione peroxidase 4 inhibitor that can reveal how metabolic state controls ferroptosis sensitivity. This guide uses bladder cancer MCT4 research to build a more discriminating assay and interpretation framework for cancer biology.

• Trametinib: From MEK Inhibition to Neural ERK Biology

  2026-09-16

  Trametinib (GSK1120212) is more than an oncology pathway probe: it can help dissect how oxidative signals reach ERK1/2 in sensory neurons. This article connects MEK inhibition, BH4-derived H2O2 signaling, and assay design while defining the translational limits of cross-domain interpretation.

• SR-202: PPARγ Antagonist Workflow Guide

  2026-09-16

  SR-202 enables controlled inhibition of PPARγ to separate receptor-dependent adipogenesis, metabolic signaling, and macrophage responses from nonspecific cell effects. This workflow guide connects validated PPARγ biology with practical assay design for insulin resistance research, obesity research, and hypothesis-driven immunometabolic studies.

7739 records 1/516 page Next 12345 下5页 Last page